NBN is altered in 2.42% of malignant solid tumor patients with NBN Mutation present in 1.27% of all malignant solid tumor patients [4].

NBN Mutation is an inclusion criterion in 31 clinical trials for malignant solid tumor, of which 25 are open and 6 are closed. Of the trials that contain NBN Mutation and malignant solid tumor as inclusion criteria, 11 are phase 1 (8 open), 7 are phase 1/phase 2 (4 open), and 13 are phase 2 (13 open) [5].

NBN is altered in 4.87% of breast carcinoma patients with NBN Mutation present in 0.91% of all breast carcinoma patients [4].

NBN Mutation is an inclusion criterion in 20 clinical trials for breast carcinoma, of which 16 are open and 4 are closed. Of the trials that contain NBN Mutation and breast carcinoma as inclusion criteria, 5 are phase 1 (4 open), 2 are phase 1/phase 2 (1 open), 11 are phase 2 (9 open), and 2 are phase 3 (2 open) [5].

NBN is altered in 1.63% of ovarian carcinoma patients with NBN Mutation present in 0.86% of all ovarian carcinoma patients [4].

NBN Mutation is an inclusion criterion in 16 clinical trials for ovarian carcinoma, of which 12 are open and 4 are closed. Of the trials that contain NBN Mutation and ovarian carcinoma as inclusion criteria, 5 are phase 1 (4 open), 2 are phase 1/phase 2 (1 open), 8 are phase 2 (7 open), and 1 is phase 3 (0 open) [5].

NBN is altered in 3.31% of prostate adenocarcinoma patients with NBN Mutation present in 0.59% of all prostate adenocarcinoma patients [4].

NBN Mutation is an inclusion criterion in 16 clinical trials for prostate adenocarcinoma, of which 15 are open and 1 is closed. Of the trials that contain NBN Mutation and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 13 are phase 2 (12 open), and 2 are phase 3 (2 open) [5].

NBN is altered in 3.34% of prostate carcinoma patients with NBN Mutation present in 0.58% of all prostate carcinoma patients [4].

NBN Mutation is an inclusion criterion in 16 clinical trials for prostate carcinoma, of which 13 are open and 3 are closed. Of the trials that contain NBN Mutation and prostate carcinoma as inclusion criteria, 4 are phase 1 (3 open), 2 are phase 1/phase 2 (1 open), 9 are phase 2 (8 open), and 1 is phase 3 (1 open) [5].

NBN is altered in 5.26% of primary peritoneal carcinoma patients [4].

NBN Mutation is an inclusion criterion in 9 clinical trials for primary peritoneal carcinoma, of which 6 are open and 3 are closed. Of the trials that contain NBN Mutation and primary peritoneal carcinoma as inclusion criteria, 4 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 3 are phase 2 (2 open), and 1 is phase 3 (0 open) [5].

NBN is altered in 0.69% of adenocarcinoma of the gastroesophageal junction patients with NBN Mutation present in 0.34% of all adenocarcinoma of the gastroesophageal junction patients [4].

NBN Mutation is an inclusion criterion in 8 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 7 are open and 1 is closed. Of the trials that contain NBN Mutation and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 2 are phase 1 (1 open), 3 are phase 1/phase 2 (3 open), and 3 are phase 2 (3 open) [5].

NBN Mutation is an inclusion criterion in 8 clinical trials for fallopian tube carcinoma, of which 5 are open and 3 are closed. Of the trials that contain NBN Mutation and fallopian tube carcinoma as inclusion criteria, 4 are phase 1 (3 open), 3 are phase 2 (2 open), and 1 is phase 3 (0 open) [5].

NBN is altered in 2.42% of non-small cell lung carcinoma patients with NBN Mutation present in 1.67% of all non-small cell lung carcinoma patients [4].

NBN Mutation is an inclusion criterion in 6 clinical trials for non-small cell lung carcinoma, of which 5 are open and 1 is closed. Of the trials that contain NBN Mutation and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 3 are phase 2 (3 open) [5].

NBN is altered in 1.03% of pancreatic adenocarcinoma patients with NBN Mutation present in 0.8% of all pancreatic adenocarcinoma patients [4].

NBN Mutation is an inclusion criterion in 6 clinical trials for pancreatic adenocarcinoma, of which 5 are open and 1 is closed. Of the trials that contain NBN Mutation and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 4 are phase 2 (4 open) [5].

NBN is altered in 3.23% of small cell lung carcinoma patients with NBN Mutation present in 2.08% of all small cell lung carcinoma patients [4].

NBN Mutation is an inclusion criterion in 5 clinical trials for small cell lung carcinoma, of which 3 are open and 2 are closed. Of the trials that contain NBN Mutation and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2 (0 open) [5].

NBN is altered in 1.76% of gastric carcinoma patients with NBN Mutation present in 1.35% of all gastric carcinoma patients [4].

NBN Mutation is an inclusion criterion in 5 clinical trials for gastric carcinoma, of which 4 are open and 1 is closed. Of the trials that contain NBN Mutation and gastric carcinoma as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [5].

NBN is altered in 4.19% of endometrial carcinoma patients with NBN Mutation present in 3.55% of all endometrial carcinoma patients [4].

NBN Mutation is an inclusion criterion in 4 clinical trials for endometrial carcinoma, of which 4 are open and 0 are closed. Of the trials that contain NBN Mutation and endometrial carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].

NBN is altered in 2.65% of colorectal carcinoma patients with NBN Mutation present in 2.11% of all colorectal carcinoma patients [4].

NBN Mutation is an inclusion criterion in 4 clinical trials for colorectal carcinoma, of which 3 are open and 1 is closed. Of the trials that contain NBN Mutation and colorectal carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [5].

NBN is altered in 1.76% of cervical carcinoma patients with NBN Mutation present in 1.51% of all cervical carcinoma patients [4].

NBN Mutation is an inclusion criterion in 4 clinical trials for cervical carcinoma, of which 3 are open and 1 is closed. Of the trials that contain NBN Mutation and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].

NBN is altered in 1.77% of gastric adenocarcinoma patients with NBN Mutation present in 1.36% of all gastric adenocarcinoma patients [4].

NBN Mutation is an inclusion criterion in 4 clinical trials for gastric adenocarcinoma, of which 4 are open and 0 are closed. Of the trials that contain NBN Mutation and gastric adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 3 are phase 2 (3 open) [5].

NBN is altered in 1.05% of pancreatic carcinoma patients with NBN Mutation present in 0.78% of all pancreatic carcinoma patients [4].

NBN Mutation is an inclusion criterion in 4 clinical trials for pancreatic carcinoma, of which 4 are open and 0 are closed. Of the trials that contain NBN Mutation and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 2 (3 open) [5].

NBN is altered in 0.74% of soft tissue sarcoma patients with NBN Mutation present in 0.26% of all soft tissue sarcoma patients [4].

NBN Mutation is an inclusion criterion in 4 clinical trials for soft tissue sarcoma, of which 3 are open and 1 is closed. Of the trials that contain NBN Mutation and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].

NBN is altered in 2.62% of urothelial carcinoma patients with NBN Mutation present in 1.96% of all urothelial carcinoma patients [4].

NBN Mutation is an inclusion criterion in 3 clinical trials for urothelial carcinoma, of which 2 are open and 1 is closed. Of the trials that contain NBN Mutation and urothelial carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (2 open) [5].

NBN is altered in 3.79% of melanoma patients with NBN Mutation present in 1.71% of all melanoma patients [4].

NBN Mutation is an inclusion criterion in 3 clinical trials for melanoma, of which 3 are open and 0 are closed. Of the trials that contain NBN Mutation and melanoma as inclusion criteria, 3 are phase 2 (3 open) [5].

NBN is altered in 1.39% of head and neck carcinoma patients with NBN Mutation present in 1.09% of all head and neck carcinoma patients [4].

NBN Mutation is an inclusion criterion in 3 clinical trials for head and neck carcinoma, of which 3 are open and 0 are closed. Of the trials that contain NBN Mutation and head and neck carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [5].

NBN is altered in 2.56% of bladder urothelial carcinoma patients with NBN Mutation present in 1.85% of all bladder urothelial carcinoma patients [4].

NBN Mutation is an inclusion criterion in 2 clinical trials for bladder urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain NBN Mutation and bladder urothelial carcinoma as inclusion criteria, 2 are phase 2 (2 open) [5].

NBN is altered in 2.09% of esophageal adenocarcinoma patients with NBN Mutation present in 1.64% of all esophageal adenocarcinoma patients [4].

NBN Mutation is an inclusion criterion in 2 clinical trials for esophageal adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain NBN Mutation and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

NBN is altered in 2.09% of esophageal carcinoma patients with NBN Mutation present in 1.6% of all esophageal carcinoma patients [4].

NBN Mutation is an inclusion criterion in 2 clinical trials for esophageal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain NBN Mutation and esophageal carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [5].

NBN is altered in 1.85% of head and neck squamous cell carcinoma patients with NBN Mutation present in 1.56% of all head and neck squamous cell carcinoma patients [4].

NBN Mutation is an inclusion criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain NBN Mutation and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [5].

NBN is altered in 1.12% of squamous cell lung carcinoma patients with NBN Mutation present in 1.12% of all squamous cell lung carcinoma patients [4].

NBN Mutation is an inclusion criterion in 2 clinical trials for squamous cell lung carcinoma, of which 1 is open and 1 is closed. Of the trials that contain NBN Mutation and squamous cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) and 1 is no phase specified (1 open) [5].

NBN is altered in 1.6% of high grade ovarian serous adenocarcinoma patients with NBN Mutation present in 0.86% of all high grade ovarian serous adenocarcinoma patients [4].

NBN Mutation is an inclusion criterion in 2 clinical trials for high grade ovarian serous adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain NBN Mutation and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) and 1 is phase 2 (1 open) [5].

NBN is altered in 1.13% of non-hodgkin lymphoma patients with NBN Mutation present in 0.79% of all non-hodgkin lymphoma patients [4].

NBN Mutation is an inclusion criterion in 2 clinical trials for non-hodgkin lymphoma, of which 1 is open and 1 is closed. Of the trials that contain NBN Mutation and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [5].

NBN is altered in 1.12% of clear cell renal cell carcinoma patients with NBN Mutation present in 0.7% of all clear cell renal cell carcinoma patients [4].

NBN Mutation is an inclusion criterion in 2 clinical trials for clear cell renal cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain NBN Mutation and clear cell renal cell carcinoma as inclusion criteria, 2 are phase 2 (2 open) [5].

NBN is altered in 1.63% of osteosarcoma patients with NBN Mutation present in 0.41% of all osteosarcoma patients [4].

NBN Mutation is an inclusion criterion in 2 clinical trials for osteosarcoma, of which 2 are open and 0 are closed. Of the trials that contain NBN Mutation and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

NBN is altered in 0.29% of gastrointestinal stromal tumor patients with NBN Mutation present in 0.15% of all gastrointestinal stromal tumor patients [4].

NBN Mutation is an inclusion criterion in 2 clinical trials for gastrointestinal stromal tumor, of which 2 are open and 0 are closed. Of the trials that contain NBN Mutation and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

NBN is altered in 5.56% of penile carcinoma patients with NBN Mutation present in 5.56% of all penile carcinoma patients [4].

NBN Mutation is an inclusion criterion in 1 clinical trial for penile carcinoma, of which 0 are open and 1 is closed. Of the trial that contains NBN Mutation and penile carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

NBN is altered in 3.34% of malignant uterine neoplasm patients with NBN Mutation present in 2.72% of all malignant uterine neoplasm patients [4].

NBN Mutation is an inclusion criterion in 1 clinical trial for malignant uterine neoplasm, of which 1 is open and 0 are closed. Of the trial that contains NBN Mutation and malignant uterine neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

NBN is altered in 2.63% of colorectal adenocarcinoma patients with NBN Mutation present in 2.1% of all colorectal adenocarcinoma patients [4].

NBN Mutation is an inclusion criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains NBN Mutation and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

NBN is altered in 2.63% of malignant intestinal neoplasm patients with NBN Mutation present in 2.1% of all malignant intestinal neoplasm patients [4].

NBN Mutation is an inclusion criterion in 1 clinical trial for malignant intestinal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains NBN Mutation and malignant intestinal neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

NBN is altered in 2.02% of malignant small intestinal neoplasm patients with NBN Mutation present in 2.02% of all malignant small intestinal neoplasm patients [4].

NBN Mutation is an inclusion criterion in 1 clinical trial for malignant small intestinal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains NBN Mutation and malignant small intestinal neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

NBN is altered in 1.92% of anal carcinoma patients with NBN Mutation present in 1.92% of all anal carcinoma patients [4].

NBN Mutation is an inclusion criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains NBN Mutation and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

NBN is altered in 2.51% of bladder carcinoma patients with NBN Mutation present in 1.85% of all bladder carcinoma patients [4].

NBN Mutation is an inclusion criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NBN Mutation and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

NBN is altered in 2.46% of lung carcinoma patients with NBN Mutation present in 1.69% of all lung carcinoma patients [4].

NBN Mutation is an inclusion criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NBN Mutation and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

NBN is altered in 2.05% of medulloblastoma patients with NBN Mutation present in 1.37% of all medulloblastoma patients [4].

NBN Mutation is an inclusion criterion in 1 clinical trial for medulloblastoma, of which 1 is open and 0 are closed. Of the trial that contains NBN Mutation and medulloblastoma as inclusion criteria, 1 is phase 1 (1 open) [5].

NBN is altered in 1.76% of malignant gastric neoplasm patients with NBN Mutation present in 1.35% of all malignant gastric neoplasm patients [4].

NBN Mutation is an inclusion criterion in 1 clinical trial for malignant gastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains NBN Mutation and malignant gastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

NBN is altered in 1.77% of malignant esophagogastric neoplasm patients with NBN Mutation present in 1.33% of all malignant esophagogastric neoplasm patients [4].

NBN Mutation is an inclusion criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains NBN Mutation and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

NBN is altered in 1.72% of gallbladder carcinoma patients with NBN Mutation present in 1.29% of all gallbladder carcinoma patients [4].

NBN Mutation is an inclusion criterion in 1 clinical trial for gallbladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NBN Mutation and gallbladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

NBN is altered in 2.3% of cancer patients with NBN Mutation present in 1.21% of all cancer patients [4].

NBN Mutation is an inclusion criterion in 1 clinical trial for cancer, of which 1 is open and 0 are closed. Of the trial that contains NBN Mutation and cancer as inclusion criteria, 1 is phase 2 (1 open) [5].

NBN is altered in 1.93% of diffuse large B-cell lymphoma patients with NBN Mutation present in 1.16% of all diffuse large B-cell lymphoma patients [4].

NBN Mutation is an inclusion criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains NBN Mutation and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

NBN is altered in 1.72% of low grade ovarian serous adenocarcinoma patients with NBN Mutation present in 1.15% of all low grade ovarian serous adenocarcinoma patients [4].

NBN Mutation is an inclusion criterion in 1 clinical trial for low grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains NBN Mutation and low grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

NBN is altered in 1.22% of glioma patients with NBN Mutation present in 1.06% of all glioma patients [4].

NBN Mutation is an inclusion criterion in 1 clinical trial for glioma, of which 1 is open and 0 are closed. Of the trial that contains NBN Mutation and glioma as inclusion criteria, 1 is phase 1 (1 open) [5].

NBN is altered in 1.5% of biliary tract carcinoma patients with NBN Mutation present in 1.03% of all biliary tract carcinoma patients [4].

NBN Mutation is an inclusion criterion in 1 clinical trial for biliary tract carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NBN Mutation and biliary tract carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

NBN is altered in 1.21% of malignant central nervous system neoplasm patients with NBN Mutation present in 1.02% of all malignant central nervous system neoplasm patients [4].

NBN Mutation is an inclusion criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains NBN Mutation and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [5].

NBN is altered in 1.31% of B-cell non-hodgkin lymphoma patients with NBN Mutation present in 0.96% of all B-cell non-hodgkin lymphoma patients [4].

NBN Mutation is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains NBN Mutation and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

NBN is altered in 1.44% of bile duct adenocarcinoma patients with NBN Mutation present in 0.96% of all bile duct adenocarcinoma patients [4].

NBN Mutation is an inclusion criterion in 1 clinical trial for bile duct adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains NBN Mutation and bile duct adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

NBN is altered in 1.44% of bile duct carcinoma patients with NBN Mutation present in 0.96% of all bile duct carcinoma patients [4].

NBN Mutation is an inclusion criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NBN Mutation and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

NBN is altered in 1.44% of cholangiocarcinoma patients with NBN Mutation present in 0.96% of all cholangiocarcinoma patients [4].

NBN Mutation is an inclusion criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains NBN Mutation and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

NBN is altered in 5.01% of invasive breast carcinoma patients with NBN Mutation present in 0.94% of all invasive breast carcinoma patients [4].

NBN Mutation is an inclusion criterion in 1 clinical trial for invasive breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NBN Mutation and invasive breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

NBN is altered in 1.78% of malignant ovarian epithelial tumor patients with NBN Mutation present in 0.81% of all malignant ovarian epithelial tumor patients [4].

NBN Mutation is an inclusion criterion in 1 clinical trial for malignant ovarian epithelial tumor, of which 1 is open and 0 are closed. Of the trial that contains NBN Mutation and malignant ovarian epithelial tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

NBN is altered in 0.73% of ampulla of vater carcinoma patients with NBN Mutation present in 0.73% of all ampulla of vater carcinoma patients [4].

NBN Mutation is an inclusion criterion in 1 clinical trial for ampulla of vater carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NBN Mutation and ampulla of vater carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

NBN is altered in 0.57% of mantle cell lymphoma patients with NBN Mutation present in 0.57% of all mantle cell lymphoma patients [4].

NBN Mutation is an inclusion criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains NBN Mutation and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

NBN is altered in 1.12% of leiomyosarcoma patients with NBN Mutation present in 0.56% of all leiomyosarcoma patients [4].

NBN Mutation is an inclusion criterion in 1 clinical trial for leiomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains NBN Mutation and leiomyosarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

NBN is altered in 0.84% of malignant mesothelioma patients with NBN Mutation present in 0.56% of all malignant mesothelioma patients [4].

NBN Mutation is an inclusion criterion in 1 clinical trial for malignant mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains NBN Mutation and malignant mesothelioma as inclusion criteria, 1 is phase 2 (1 open) [5].

NBN is altered in 0.48% of multiple myeloma patients with NBN Mutation present in 0.48% of all multiple myeloma patients [4].

NBN Mutation is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains NBN Mutation and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [5].

NBN is altered in 0.28% of neuroblastoma patients with NBN Mutation present in 0.28% of all neuroblastoma patients [4].

NBN Mutation is an inclusion criterion in 1 clinical trial for neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains NBN Mutation and neuroblastoma as inclusion criteria, 1 is phase 1 (1 open) [5].

NBN Mutation is an inclusion criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NBN Mutation and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

NBN is altered in 0.89% of esophageal squamous cell carcinoma patients [4].

NBN Mutation is an inclusion criterion in 1 clinical trial for esophageal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NBN Mutation and esophageal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

NBN is altered in 0.68% of Ewing sarcoma patients [4].

NBN Mutation is an inclusion criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains NBN Mutation and Ewing sarcoma as inclusion criteria, 1 is phase 1 (1 open) [5].

NBN is altered in 0.3% of mature T-cell and NK-cell non-hodgkin lymphoma patients [4].

NBN Mutation is an inclusion criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains NBN Mutation and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

NBN Mutation is an inclusion criterion in 1 clinical trial for ovarian clear cell adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains NBN Mutation and ovarian clear cell adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

NBN Mutation is an inclusion criterion in 1 clinical trial for pancreatic ductal adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains NBN Mutation and pancreatic ductal adenocarcinoma as inclusion criteria, 1 is phase 2 (0 open) [5].

NBN is altered in 2.37% of rhabdomyosarcoma patients [4].

NBN Mutation is an inclusion criterion in 1 clinical trial for rhabdomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains NBN Mutation and rhabdomyosarcoma as inclusion criteria, 1 is phase 1 (1 open) [5].

NBN Mutation is an inclusion criterion in 1 clinical trial for vaginal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains NBN Mutation and vaginal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

NBN Mutation is an inclusion criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains NBN Mutation and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].